Product Images Sarclisa

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 4 images provide visual information about the product associated with Sarclisa NDC 0024-0654 by Sanofi-aventis U.s. Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Figure 1 - sarclisa 01

Figure 1 - sarclisa 01

This appears to be a statistical analysis of patients with Isa-Pd and Tsa-Pd Pd, with a comparison to a comparator regimen. The analysis includes a hazard ratio and median months of the patients at risk. There are also graphs displaying the probability of PFS over time.*

PRINCIPAL DISPLAY PANEL - 100 mg/5 mL Vial Carton - sarclisa 02

PRINCIPAL DISPLAY PANEL - 100 mg/5 mL Vial Carton - sarclisa 02

This is a table containing statistical data for two different types of treatment, namely Isa-Kd and Kd. The data suggests that Isa-Kd has a better median progression-free survival than Kd. Furthermore, the table includes the Hazard ratio (HR) and the confidence interval (CI) which indicate the reliability of the data. Patients' probability of PFS is also presented over time.*

PRINCIPAL DISPLAY PANEL - 500 mg/25 mL Vial Carton - sarclisa 03

PRINCIPAL DISPLAY PANEL - 500 mg/25 mL Vial Carton - sarclisa 03

SARCLISA is an isatuximab-irfc injection used for intravenous infusion. Each mL of solution contains 20 mg of isatuximab-fc along with other substances like histidine hydrochloride monohydrate, polysorbate 80, sucrose and water for injection. The prescribed dosage and administration procedure should be followed carefully. The vial must be stored refrigerated at 36°F-46°F, protected from light, not shaken, and not frozen. SARCLISA is manufactured by Sanofi-aventis US, LLC and should be used only as per standard medical guidelines.*

sarclisa 04

sarclisa 04

SARCLISA (isatuximab-irfc) Injection is a medication administered through the intravenous route, for which one 25mL single-dose vial is sufficient. It is produced and distributed by Sanofiaventis US, LLC. SARCLISA comes in doses of 500mg/25mL or 20mg/mL, and it should be stored in the refrigerator at 2-8°C to protect it from light. It is important not to shake or freeze the medication. SARCLISA's dosage and administration processes must be done as per the prescribing information. The preparation is not suitable for children, and once it is no longer required or has passed the expiration date, the unused portion should be disposed of. The contents of the vial contain the active Isatuximab-rc ingredient (20mg/mL) and other additives necessary for the preparation. The text does not provide information about the medical conditions for which SARCLISA is suitable.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.